Recap: Fate Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Fate Therapeutics (NASDAQ:FATE) reported Q4 earnings with an EPS of $-0.45, beating estimates by 13.0% but with a revenue decrease of $42.68 million from the previous year. Despite beating EPS estimates in past quarters, such positive results were followed by a share price drop the next day.
February 26, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fate Therapeutics reported a Q4 EPS of $-0.45, surpassing estimates by 13.0%, but saw a significant revenue drop from the previous year.
Although FATE beat EPS estimates, the significant year-over-year revenue drop and historical context of share price drops following earnings beats suggest a potential negative short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100